ライフサイエンスコーパス: matching placebo

1 ed to receive either 300 mg clopidogrel or a matching placebo administered a minimum of 3 h and a max

2 received 1 mg crystalline vitamin B-12 or a matching placebo as a daily oral tablet for 12 mo.

3 parib (as capsules; 400 mg twice a day) or a matching placebo by an interactive voice response system

4 release niacin and 40 mg of laropiprant or a matching placebo daily.

5 y 50,000 IU every other week for 40 wk) or a matching placebo for 1 y.

6 ation at 1 of 2 doses (2000 or 4000 IU) or a matching placebo for 16 wk.

7 l followed by 4000 IU cholecalciferol/d or a matching placebo for 16 wk.

8 received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.

9 00 mg, or 150 and 600 mg, respectively, or a matching placebo for a period of 40 weeks, and then to u

10 ion > or = 12 hours before angiography) or a matching placebo infusion with provisional use of eptifi

11 eeks of treatment with either bupropion or a matching placebo pill (double-blind).

12 folic acid, vitamin B6, and vitamin B12 or a matching placebo, and were treated for 7.3 years from Ap

13 nhaled salmeterol (100 mug twice daily) or a matching placebo.

14 month course of 900 mg INH twice weekly or a matching placebo.

15 c acid, vitamin B(6), and vitamin B(12) or a matching placebo.

16 d 2.5 mg of medroxyprogesterone acetate or a matching placebo.

17 rbal extracts (Vineyard [V]), JP alone, or a matching placebo.

18 to once-daily oral fidaxomicin (200 mg) or a matching placebo.

19 s (27.3%) receiving a mood stabilizer plus a matching placebo (P=0.40).

20 pressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to rout

21 d to continue spironolactone or to receive a matching placebo.

22 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years.

23 docetaxel (n=402) or the same regimen with a matching placebo replacing pertuzumab (n=406).

24 ects of 40 mEq K/d as KCl supplements with a matching placebo, taken for 3 mo, on measures of potassi

25 5), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-matching pla

26 -matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching placebo (n=62

27 n=79), 350 mg (n=79), and 420 mg (n=80), and matching placebo (n=79) every 4 weeks.

28 2 received oral valacyclovir, acyclovir, and matching placebo in random order for 7-week periods.

29 3) for 28 days, or 40 mg of prednisolone and matching placebo (n=137) for 28 days.

30 mycin 125 mg four times a day with cadazolid-matching placebo suspension twice daily for 10 days, wit

31 tching placebo during weeks 1-12), or double-matching placebo group.

32 All regimens included matching placebo such that all volunteers received ident

33 All treatment arms included matching placebos.

34 nous nivolumab every 2 weeks plus ipilimumab-matching placebo during weeks 1-12), or double-matching

35 r dulaglutide (1.5 mg) or an equal volume of matching placebo.

36 .5 mg, whereas those on placebo continued on matching placebo.

37 astatin daily following surgery (n = 102) or matching placebo (n = 97).

38 to receive 10 mg/d of ramipril (n = 106) or matching placebo (n = 106) for 24 weeks.

39 eive oral paricalcitol, 2 mug/d (n =115), or matching placebo (n = 112).

40 ne, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care

41 randomised to receive regorafenib (n=133) or matching placebo (n=66).

42 taining either 0.625 mg of CEE (n = 1387) or matching placebo (n = 1421).

43 , both irbesartan and lipoic acid (n=15), or matching placebo (n=14) for 4 weeks.

44 eceived either MC-1, 250 mg/d (n = 1519), or matching placebo (n = 1504) immediately before and for 3

45 to twice daily aciclovir 400 mg (n=1637) or matching placebo (n=1640) for 12-18 months, and were see

46 twice-daily losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline

47 intramuscular injections of 250 mg of 17P or matching placebo, starting at 16 to 20 weeks of gestatio

48 reatment with daily oral lithium (n = 18) or matching placebo (n = 16) at the primary outcome showed

49 total cumulative dose = 600 mg; n = 181) or matching placebo (n = 88).

50 ining 100 mg of total isoflavones (n=193) or matching placebo (n=193) in 2 divided doses administered

51 partial NMDA agonist d-cycloserine (n=20) or matching placebo capsules (n=27).

52 atorvastatin the morning after (n = 206) or matching placebo (n = 210), and resumed taking the previ

53 5 mg of spironolactone once daily (n=213) or matching placebo (n=209) with 12 months of follow-up.

54 one titrated from 15 mg to 45 mg (n=2605) or matching placebo (n=2633), to be taken in addition to th

55 ), 8 mg/day (n=284), or 10 mg/day (n=283) or matching placebo (n=278) for 14 weeks.

56 g of lean body wt per day; n=52) NaHCO(3) or matching placebo (n=52).

57 on day 1 and 2 mg orally on days 2 to 3) or matching placebo, granisetron (2 mg orally on days 1 to

58 aricalcitol (1 mug) one time daily (n=30) or matching placebo (n=30) for 52 weeks.

59 hromycin (12 mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each pr

60 Vitamin D3 (2400 IU/d; n = 315) or matching placebo tablets (n = 308) from pregnancy week 2

61 ed-release 1000 mg twice daily, n = 3279) or matching placebo (n = 3281), and followed up for a media

62 0 mg orally twice daily, on days -2 to 5) or matching placebo.

63 ned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108).

64 Eszopiclone, 3 mg (n = 76), or matching placebo (n = 78) for the first 14 nights of CPA

65 ients to receive losartan, 100 mg (n=77), or matching placebo (n=76) within 3 months of transplantati

66 (n=79), 105 mg (n=79), or 140 mg (n=78), or matching placebo (n=78) every 2 weeks; or AMG 145 280 mg

67 followed by 300 mg at weeks 2, 4, and 8), or matching placebo.

68 at baseline and 225 mg at weeks 4 and 8), or matching placebo.

69 dministered ramipril 10 mg per day (n=82) or matching placebo (n=83) for 24 weeks in a randomized, do

70 of 10 to 20 mg/d of escitalopram (n = 85) or matching placebo (n = 92).

71 5 mg medroxyprogesterone acetate (n=8506) or matching placebo (n=8102).

72 e of 1 mg, 2.5 mg, 5 mg, or 10 mg TA-8995 or matching placebo; 10 mg TA-8995 plus 20 mg atorvastatin;

73 avenous then 200 mg oral daily; n=22,929) or matching placebo (n=22,923).

74 receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314).

75 ocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 m

76 subjects received 4 rounds of albendazole or matching placebo with 3-month intervals, for 3 consecuti

77 location to receive 1 mg oral anastrozole or matching placebo every day for 5 years.

78 tamin K antagonist and to receive aspirin or matching placebo for 6 months.

79 atients received 80 mg atorvastatin (ATV) or matching placebo for a 12-week treatment period with a m

80 o receive two injections of betamethasone or matching placebo 24 hours apart.

81 omized to treatment with either cangrelor or matching placebo (bolus followed by 2-hour infusion).

82 n a 1:1 ratio to receive either LY-CoV555 or matching placebo.

83 ere randomly assigned to receive cytisine or matching placebo for 25 days; participants in both group

84 ted dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 months.

85 e fish oil capsules (four 1-g capsules/d) or matching placebo on day 7 after graft creation.

86 zed to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours of admission.

87 d weight-based ribavirin (1000-1200 mg/d) or matching placebo.

88 misation to rifampicin 300 mg twice daily or matching placebo (50 mg riboflavin capsules), stratified

89 rtan at a target dose of 32 mg once daily or matching placebo and followed up for a median of 38 mont

90 ere randomized to 40 mg simvastatin daily or matching placebo for 5 years, which, on average, reduced

91 :1) to receive oral tamoxifen 20 mg daily or matching placebo for 5 years.

92 folic acid and 30 mg elemental zinc daily or matching placebo for 6 months.

93 ly assigned sildenafil 40 mg thrice daily or matching placebo for 9 weeks.

94 either 500 mg of levofloxacin once daily or matching placebo for seven days during the expected neut

95 omly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-co

96 ther nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacc

97 international units capsules twice-daily or matching placebo tablets and capsules.

98 o receive 0.5 mg of colchicine once daily or matching placebo.

99 atin (20 mg) plus ezetimibe (10 mg) daily or matching placebo.

100 zidine 35 mg modified-release twice daily or matching placebo.

101 received either anacetrapib 100 mg daily or matching placebo.

102 oral vandetanib 300 mg per day once daily or matching placebo.

103 an (n=3803, titrated to 32 mg once daily) or matching placebo (n=3796), and followed up for at least

104 sease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 mo

105 nuous oral sorafenib (400 mg twice-daily) or matching placebo combined with TACE using drug-eluting b

106 ), to oral RO5093151 (200 mg twice daily) or matching placebo for 12 weeks.

107 rated to a maximum dose of 2700 mg daily) or matching placebo for 16 weeks.

108 ns of atopaxar (50, 100, or 200 mg daily) or matching placebo for 24 weeks and followed up for an add

109 d to add raltegravir (400 mg twice daily) or matching placebo for 24 weeks.

110 tide (dose escalated to 14 mg once daily) or matching placebo for 26 weeks, in addition to background

111 bosis to receive vorapaxar (2.5 mg daily) or matching placebo in a 1:1 ratio.

112 ding dose followed by 7.5 mg twice daily) or matching placebo in a 3:3:2 ratio.

113 to either metformin (850 mg twice daily) or matching placebo in block sizes of four.

114 first day followed by 75 to 100 mg daily) or matching placebo plus aspirin.

115 ther cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks.

116 00 mg in two 150 mg tablets, twice daily) or matching placebo tablets using an interactive voice and

117 mized to receive rimonabant (20 mg daily) or matching placebo, and underwent coronary intravascular u

118 ose followed by 50, 100, or 200 mg daily) or matching placebo.

119 andesartan (target dose 32 mg once daily) or matching placebo.

120 lutamide (four 60 mg tablets, once daily) or matching placebo.

121 5, or 10 mg oral preladenant twice daily, or matching placebo for 12 weeks.

122 usted to a maximum dose of 600 mg per day or matching placebo for up to 8 weeks.

123 d either 150 mg of anacetrapib once a day or matching placebo with a meal for 10 days in each crossov

124 to receive oral neratinib 240 mg per day or matching placebo.

125 6 months of oral spironolactone 25 mg/day or matching placebo.

126 assigned to candesartan 16 mg once a day or matching placebo.

127 ceive 1 year of oral neratinib 240 mg/day or matching placebo.

128 arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months.

129 2 mg per kilogram of body weight per day) or matching placebo for one year and were followed for an a

130 eive idebenone (300 mg three times a day) or matching placebo orally for 52 weeks.

131 d to daily sorafenib (400 mg twice a day) or matching placebo plus gemcitabine (1,250 mg/m(2) per day

132 receive oral buparlisib (100 mg per day) or matching placebo starting on day 1 of cycle 1, plus intr

133 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on day 15 of cycle 1, plus in

134 ACAT inhibitor pactimibe (100 mg per day) or matching placebo.

135 zine (12 mg/day, 24 mg/day, or 36 mg/day) or matching placebo.

136 ally three times daily (40 mg/kg per day) or matching placebo.

137 (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 weeks after engraftment.

138 vely, and 25 mg daily for another 8 days, or matching placebo at the same times.

139 domly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months.

140 tered oral NAC (3000 mg in divided doses) or matching placebo 165 min before the infusion of saline a

141 al administration of 20 mg of doxycycline or matching placebo pill twice a day at least 2 days prior

142 o receive 10 mg/kg intravenous durvalumab or matching placebo 1-42 days after concurrent chemoradioth

143 0 mg of vitamin C and 400 IU of vitamin E or matching placebo between the 9th and 16th weeks of pregn

144 three), to receive once-daily eltrombopag or matching placebo dose adjusted from 50 mg to a maximum d

145 receive 150 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 mon

146 10 mg/kg midday, and 20 mg/kg in evening) or matching placebo for 48 weeks.

147 Fasudil or matching placebo was force-titrated from 20 mg three tim

148 ctive dose of apomorphine sublingual film or matching placebo in a 12-week, double-blind maintenance

149 Patients received either fludrocortisone or matching placebo at highest tolerated doses from 0.05 mg

150 g/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until diseas

151 oxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily.

152 nation tenofovir-emtricitabine (TDF-FTC), or matching placebo--and followed monthly for up to 36 mont

153 or secondary RP received 0.9% MQX-503 gel or matching placebo during the treatment period.

154 ssigned to receive either subcutaneous GH or matching placebo titrated to the upper quartile of norma

155 ver 10 min then infusion of 1 g over 8 h) or matching placebo.

156 d by a constant infusion of 2 g per hour, or matching placebo.

157 lus paclitaxel (80 mg/m(2) intravenously) or matching placebo plus paclitaxel.

158 s of radium-223 (50 kBq/kg intravenously) or matching placebo, with one injection given every 4 weeks

159 er kilogram of body weight intravenously) or matching placebo; one injection was administered every 4

160 ral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and 8 weeks.

161 , 70, 210, or 420 mg SC; 21 or 420 mg IV; or matching placebo.

162 assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles f

163 ipants to receive 400 mug oral vitamin K2 or matching placebo once daily for a year.

164 s either intravenous ramucirumab 10 mg/kg or matching placebo on day 1 of repeating 21-day cycles, un

165 either intravenous ramucirumab (10 mg/kg) or matching placebo once every 2 weeks.

166 nous injections of radium-223 (55 kBq/kg) or matching placebo once every 4 weeks.

167 doses over 10 weeks of AMG 714 (8 mg/kg) or matching placebo.

168 nous injections of radium-223 (50 kBq/kg) or matching placebo; one injection was given every 4 weeks.

169 under double-blind conditions to lithium or matching placebo before receiving an additional three in

170 1 to receive once-daily, oral mavacamten, or matching placebo for 30 weeks.

171 Metformin or matching placebo titrated up to 500 mg twice daily for c

172 AH were to be randomized to aspirin 81 mg or matching placebo and simvastatin 40 mg or matching place

173 response system to oral rimegepant 75 mg or matching placebo every other day for 12 weeks (double-bl

174 aily oral treatment with linagliptin 5 mg or matching placebo for 24 weeks.

175 tronidazole 750 mg plus miconazole 200 mg or matching placebo for 5 consecutive nights each month for

176 or twice-daily doses of ABI-H0731 800 mg or matching placebo for 7 days.

177 eive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine

178 h PAH were randomized to anastrozole 1 mg or matching placebo in a 2:1 ratio.

179 Patients received atezolizumab 840 mg or matching placebo intravenously on day 1 and day 15 of ev

180 to receive either oral naldemedine 0.2 mg or matching placebo once a day for 12 weeks.

181 s were assigned to empagliflozin of 10 mg or matching placebo once daily on guideline-driven HF thera

182 ended-release exenatide at a dose of 2 mg or matching placebo once weekly.

183 Ramelteon 8 mg or matching placebo starting the night prior to surgery and

184 eceive tozadenant 60, 120, 180, or 240 mg or matching placebo twice daily for 12 weeks.

185 Thiamine 200 mg or matching placebo twice daily for 7 days or until hospita

186 Patients received oral vorinostat 300 mg (or matching placebo) twice daily on days 1, 2, 3, 8, 9, 10,

187 The study drugs (acetylcysteine 1200 mg or matching placebo) were administered orally twice daily f

188 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 w

189 -based system to receive resmetirom 80 mg or matching placebo, orally once a day.

190 cycle 1) with either capivasertib 400 mg or matching placebo, orally twice daily on an intermittent

191 ither twice-daily oral ranolazine 1000 mg or matching placebo.

192 or matching placebo and simvastatin 40 mg or matching placebo.

193 omly assigned (1:1) to gefitinib (500 mg) or matching placebo by simple randomisation with no stratif

194 e randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition to usual treat

195 ts per day of sodium clodronate (2080 mg) or matching placebo for up to 3 years (metastatic disease)

196 se of SCH 530348 (10 mg, 20 mg, or 40 mg) or matching placebo in a 3:1 ratio in a multicentre interna

197 ed 1:1 to receive escitalopram (10-20 mg) or matching placebo in addition to optimal heart failure th

198 ive either NDI-010976 (20, 50, or 200 mg) or matching placebo in period 1, followed by the alternate

199 f inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450.

200 1:1:1 ratio to ozanimod (0.5 mg or 1 mg) or matching placebo once daily for 24 weeks by an independe

201 eive ABI-H0731 (100, 200, 300, or 400 mg) or matching placebo once daily for 28 days.

202 either a low dose of varenicline (0.5 mg) or matching placebo pill (double-blind, random order) befor

203 e 4) to receive either denosumab (120 mg) or matching placebo subcutaneously every 3-4 weeks, startin

204 e) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation f

205 of ABI-H0731 (100, 300, 600, or 1000 mg) or matching placebo, or once-daily or twice-daily doses of

206 aily erythromycin ethylsuccinate (400 mg) or matching placebo.

207 N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71).

208 Doxycycline, 200 mg, or matching placebo daily for 12 months.

209 ions of AMG 145 70 mg, 105 mg, or 140 mg, or matching placebo every 2 weeks; or subcutaneous injectio

210 ons of AMG 145 280 mg, 350 mg, or 420 mg, or matching placebo every 4 weeks.

211 Hydroxychloroquine, 400 mg, or matching placebo once daily for 48 weeks.

212 mg], n = 50 [30 mg], and n = 51 [40 mg]) or matching placebo (n = 76) for 20 weeks of treatment.

213 ing ephedra [12 mg] and caffeine [40 mg]) or matching placebo were administered in a crossover fashio

214 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition to accepted t

215 ly assigned to either NV1FGF at 0.2 mg/mL or matching placebo (visually identical) in a 1:1 ratio.

216 r 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections.

217 of 50 mug, 150 mug, 300 mug, or 600 mug, or matching placebo (n=55 in each group), or to open-label

218 fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks.

219 fter treatment with either sodium nitrite or matching placebo.

220 o either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years.

221 eceived either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4.

222 receive 4.5 gm or 6 gm of sodium oxybate or matching placebo once per night for 8 weeks.

223 anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients).

224 ase inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks.

225 rget dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

226 l sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 weeks.

227 Pioglitazone or matching placebo.

228 the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosino

229 containing either 400 mg of progesterone or matching placebo twice daily, from the time at which the

230 ocated by computer to either the quadpill or matching placebo for 4 weeks; this treatment was followe

231 specific volume of study drug (reslizumab or matching placebo) on the basis of the patient's body wei

232 mg/d based on tolerability and response) or matching placebo (n = 99).

233 ceive 420-mg silymarin, 700-mg silymarin, or matching placebo administered 3 times per day for 24 wee

234 ipants in a 1:1 ratio to either sorafenib or matching placebo.

235 Oral doses of 0.5 or 2.0 g SRT2104 or matching placebo were administered once daily for 28 day

236 h 4:1 allocation to oral AA (87 subjects) or matching placebo (23 subjects).

237 once-daily, fixed-dose combination tablet or matching placebo for 12 weeks.

238 received oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 week oral lead-in

239 L-thyroxine or matching placebo with mock dose titration.

240 sartan (increased to 300 mg as tolerated) or matching placebo.

241 ologic intervention using oral vancomycin or matching placebo (NCT02037295).

242 ere randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 we

243 her oral odanacatib (50 mg once per week) or matching placebo.

244 a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks.

245 (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardi

246 o 25 mg rifalazil once weekly for 8 weeks or matching placebo.

247 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.

248 f dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily

249 se of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization.

250 g or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for

251 weeks (Q2W) x3, 420 mg every 4 weeks x2, or matching placebo.

252 0 mg per day for age 6 months to 5 years) or matching placebo.

253 ombination of the 2 medications (n = 20), or matching placebos (n = 24).

254 eceive dabrafenib plus trametinib (n=438) or matching placebos (n=432).

255 mined according to body weight) (group A) or matching placebos (group B).

256 d) plus alpha-lipoic acid (ALA; 600 mg/d) or matching placebos for 6 months (NCT00237718); 238 patien

257 y) with ribavirin (1000 or 1200 mg daily) or matching placebos during the 12-week double-blind period

258 y) plus oral trametinib (2 mg once daily) or matching placebos for 12 months.

259 biraterone acetate plus prednisone group) or matching placebos plus ADT (placebo group); each treatme

260 OBI/FTC/TDF or EFV/FTC/TDF, once daily, plus matching placebo.

261 ive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once daily.

262 =628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an a

263 lbendazole-matching placebo and praziquantel-matching placebo (n=628).

264 il hospital discharge (n = 84) or to receive matching placebo (n = 76).

265 administered according to body weight or to matching placebo for ribavirin.

266 eeks (q4-wk), every 12 weeks (q12-wk), or to matching placebo to week 52.

267 ed to vitamin D3 and 9172 were randomized to matching placebo.

268 cadazolid 250 mg twice daily with vancomycin-matching placebo capsule four times daily or oral vancom

269 iacin with 40 mg of laropiprant daily versus matching placebo, in addition to effective statin-based

270 atin 20 mg plus ezetimibe 10 mg daily versus matching placebo.

271 trial of sertraline 50 to 200 mg/day versus matching placebo for 12 weeks.

272 Nilotinib 150 mg versus matching placebo was taken orally once daily for 26 week

273 lgia within 3 weeks of open-label use versus matching placebo.

274 n E (alpha-tocopherol) 1,000 U daily, versus matching placebos in 1,005 asymptomatic, apparently heal

275 ablet containing either 0.625 mg/d of CEE vs matching placebo; in the estrogen plus progestin trial,

276 of treatment with d-vitamin E (1600 IU/d) vs matching placebo.

277 lus and 1-mg/kg per hour 5-hour infusion, vs matching placebo.

278 Latrepirdine (20 mg) vs matching placebo administered orally 3 times daily for 2

279 ning CEE (0.625 mg/d) plus MPA (2.5 mg/d) vs matching placebos.

280 fa, 40,000 U subcutaneously, once weekly vs. matching placebo.

281 igate oral iron polysaccharide compared with matching placebo with the primary end point of change in

282 placebo, for aspirin alone as compared with matching placebo, and for the polypill plus aspirin as c

283 omes for the polypill alone as compared with matching placebo, for aspirin alone as compared with mat

284 ve either oral tamoxifen 20 mg per day (with matching placebo in place of anastrozole) or oral anastr

285 zole) or oral anastrozole 1 mg per day (with matching placebo in place of tamoxifen) for 5 years.

286 b (45 mg/day) or erlotinib (150 mg/day) with matching placebo.

287 75 mg bictegravir or 50 mg dolutegravir with matching placebo plus the fixed-dose combination of 200

288 e 300 mg (the dolutegravir group), each with matching placebo, once daily for 144 weeks.

289 de 25 mg (the dolutegravir group), each with matching placebo, once daily for 144 weeks.

290 ofovir disoproxil fumarate 300 mg, each with matching placebo.

291 or 300 mg tenofovir disoproxil fumarate with matching placebo.

292 e (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

293 tenofovir disoproxil fumarate (300 mg), with matching placebo, once daily for 96 weeks.

294 tenofovir disoproxil fumarate (300 mg), with matching placebo.

295 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once a day for 144 weeks.

296 abacavir 600 mg, and lamivudine 300 mg, with matching placebo, once daily for 144 weeks.

297 ibavirin versus oseltamivir monotherapy with matching placebo for the treatment of influenza in 50 si

298 0 IU of oxytocin intramuscularly, along with matching placebos for the treatment they did not receive

299 or based regimen); regimens were masked with matching placebos.

300 pitavastatin 4 mg or pravastatin 40 mg with matching placebos once daily orally for 12 weeks, follow